drugset / Trial / NCT03518554
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
Timeline
- Start
- 2018-04-23
- Primary completion
- 2022-02-03
- Completion
- 2022-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JAB-3068 | Small molecule | — | Oral |